The GH-IGF-I axis and breast cancer

被引：101

作者：

Laban, C

Bustin, SA

Jenkins, PJ ^{[1
]}

机构：

[1] Univ London St Bartholomews Hosp Med Coll, Dept Endocrinol, London EC1A 7BE, England

[2] Royal London Hosp, Acad Dept Surg, London E1 1BB, England

[3] Univ London St Bartholomews Hosp Med Coll, Dept Breast Surg, London EC1A 7BE, England

来源：

TRENDS IN ENDOCRINOLOGY AND METABOLISM | 2003年 / 14卷 / 01期

关键词：

D O I：

10.1016/S1043-2760(02)00003-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis plays a fundamental role in the development of the breast. The maintenance of breast tissue architecture is aided by its effect on proliferation, differentiation and apoptosis. There has been increasing recognition of its role as a major determinant of breast cancer and, more recently, its involvement in the development of resistance to both tamoxifen and an important novel therapy for advanced disease, trastuzumab (Herceptin(R)). Here, we discuss the influence of the GH-IGF-I axis in normal mammary development and homeostasis, its putative role in breast tumorigenesis and its interactions with estrogen signalling.

引用

收藏

页码：28 / 34

页数：7

相关论文

共 73 条

[1] Role of AKT1 in 17β-estradiol- and insulin-like growth factor I (IGE-I)-dependent proliferation and prevention of apoptosis in MCF-7 breast carcinoma cells [J].

Ahmad, S ;

Singh, N ;

Glazer, RI .

BIOCHEMICAL PHARMACOLOGY, 1999, 58 (03) :425-430

[2] Unraveling resistance to trastuzumab (Herceptin): Insulin-like growth factor-I receptor, a new suspect [J].

Albanell, J ;

Baselga, J .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (24) :1830-1832

[3] BLOCKADE OF THE TYPE-I SOMATOMEDIN RECEPTOR INHIBITS GROWTH OF HUMAN-BREAST CANCER-CELLS IN ATHYMIC MICE [J].

ARTEAGA, CL ;

KITTEN, LJ ;

CORONADO, EB ;

JACOBS, S ;

KULL, FC ;

ALLRED, DC ;

OSBORNE, CK .

JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (05) :1418-1423

[4] A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma [J].

Bajetta, E ;

Procopio, G ;

Ferrari, L ;

Martinetti, A ;

Zilembo, N ;

Catena, L ;

Alú, M ;

Della Torre, S ;

Alberti, D ;

Buzzoni, R .

CANCER, 2002, 94 (02) :299-304

[5] Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells [J].

Balañá, ME ;

Labriola, L ;

Salatino, M ;

Movsichoff, F ;

Peters, G ;

Charreau, EH ;

Elizalde, PV .

ONCOGENE, 2001, 20 (01) :34-47

[6] MAMMARY-CANCER IN TRANSGENIC MICE EXPRESSING INSULIN-LIKE GROWTH-FACTOR-II (IGF-II) [J].

BATES, P ;

FISHER, R ;

WARD, A ;

RICHARDSON, L ;

HILL, DJ ;

GRAHAM, CF .

BRITISH JOURNAL OF CANCER, 1995, 72 (05) :1189-1193

[7] Somatostatin and growth hormone-releasing hormone in normal and tumoral human breast tissue: Endogenous content, in vitro pulsatile release, and regulation [J].

Benlot, C ;

Levy, L ;

Fontanaud, P ;

Roche, A ;

Rouannet, P ;

Joubert, D .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (02) :690-696

[8] Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women [J].

Bonanni, B ;

Johansson, H ;

Gandini, S ;

Guerrieri-Gonzaga, A ;

Torrisi, R ;

Sandri, MT ;

Cazzaniga, M ;

Mora, S ;

Robertson, C ;

Lien, EA ;

Decensi, A .

BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (01) :21-27

[9] Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up [J].

Bontenbal, M ;

Foekens, JA ;

Lamberts, SWJ ;

de Jong, FH ;

van Putten, WLJ ;

Braun, HJ ;

Burghouts, JTM ;

van der Linden, GHM ;

Klijn, JGM .

BRITISH JOURNAL OF CANCER, 1998, 77 (01) :115-122

[10]

Campbell MJ, 2001, J CLIN PATHOL-MOL PA, V54, P307

← 1 2 3 4 5 6 7 8 →